Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FoxD2-AS1is a prognostic factor in glioma and promotes temozolomide resistance in a O6-methylguanine-DNA methyltransferase-dependent manner

1 Jan 2019

Abstract excerpt

Glioma is the most common brain tumor with a dismal prognosis. While temozolomide (TMZ) based chemotherapy significantly improves survival in glioma patients, resistance against this compound commonly leads to glioma treatment failure. Overexpression of long-noncoding RNA (LncRNA) FoxD2 adjacent opposite strand RNA 1 (FoxD2-AS1) was identified to promote glioma development, but the role in TMZ resistance remains...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related molecular mechanisms research
Share to Glioma Diagnosis and Treatment
Share to Mycobacterium research and diagnosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31680769
DOI: 10.4196/kjpp.2019.23.6.475

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FoxD2-AS1is a prognostic factor in glioma and promotes temozolomide resistance in a O6-methylguanine-DNA methyltransferase-dependent mannerPMID 31680769Read ↗

FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide.Semantic proximity Read ↗

FXYD2 mRNA Expression Represents a New Independent Factor That Affects Survival of Glioma Patients and Predicts Chemosensitivity of Patients to TemozolomideSemantic proximity Read ↗

Integrated Analysis Identifies MEOX2 as a Malignant Driver and Prognostic Biomarker in Brain GliomaSemantic proximity Read ↗

Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastomaSemantic proximity Read ↗

Knockdown lncRNA DLEU1 Inhibits Gliomas Progression and Promotes Temozolomide Chemosensitivity by Regulating AutophagySemantic proximity Read ↗

m1A RNA Methylation Regulators Contribute To Malignant Progression And Have Clinical Prognostic Impact In GliomasSemantic proximity Read ↗

A Comprehensive Review of miRNAs and Their Epigenetic Effects in GlioblastomaSemantic proximity Read ↗

ZMYND8 as a novel diagnostic and prognostic biomarker in GliomaSemantic proximity Read ↗

The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma MultiformeSemantic proximity Read ↗

Forkhead box transcription factors (FOXOs and FOXM1) in glioma: from molecular mechanisms to therapeuticsSemantic proximity Read ↗

Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastomaSemantic proximity Read ↗

Combined <i>MGMT</i> Expression and MMR Deficiency Underlie Poor Outcomes of Temozolomide in <i>IDH</i> -Wildtype Grade 2 GliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.